These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2500842)

  • 1. Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction.
    Tranchesi B; Bellotti G; Chamone DF; Verstraete M
    Am J Cardiol; 1989 Jul; 64(3):229-32. PubMed ID: 2500842
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
    Bär FW; Meyer J; Vermeer F; Michels R; Charbonnier B; Haerten K; Spiecker M; Macaya C; Hanssen M; Heras M; Boland JP; Morice MC; Dunn FG; Uebis R; Hamm C; Ayzenberg O; Strupp G; Withagen AJ; Klein W; Windeler J; Hopkins G; Barth H; von Fisenne MJ
    Am J Cardiol; 1997 Mar; 79(6):727-32. PubMed ID: 9070549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombolytic (fibrinolytic) agents for treatment of ischemic heart disease].
    Nagao K; Kanmatsuse K
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():641-6. PubMed ID: 12735044
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombolytic therapy for acute myocardial infarction--round 2.
    Lancet; 1988 Mar; 1(8585):565-7. PubMed ID: 2894496
    [No Abstract]   [Full Text] [Related]  

  • 6. How should intravenous thrombolytic agents for acute myocardial infarction be selected?
    Topol EJ
    Cardiovasc Clin; 1990; 21(1):57-75; discussion 76-8. PubMed ID: 2143103
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
    Motomiya T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pro-urokinase for infarct therapy].
    Spiecker M; Meyer J
    Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
    Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
    J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute myocardial infarction: thrombolytic therapy in ambulance?].
    Martens F
    Internist (Berl); 2001 May; 42(5):682-5. PubMed ID: 11400575
    [No Abstract]   [Full Text] [Related]  

  • 15. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.
    Vermeer F; Bösl I; Meyer J; Bär F; Charbonnier B; Windeler J; Barth H
    J Thromb Thrombolysis; 1999 Aug; 8(2):143-50. PubMed ID: 10436145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
    Maksimenko AV; Tischenko EG
    J Thromb Thrombolysis; 1999 Jun; 7(3):307-12. PubMed ID: 10373713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents.
    Collen D; Stump DC; Van de Werf F
    Am Heart J; 1986 Nov; 112(5):1083-4. PubMed ID: 3096127
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroradiologists intervene with new therapy for stroke.
    Sandrick K
    Diagn Imaging (San Franc); 1999 Jan; 21(1):19-20. PubMed ID: 11692376
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of association between raised serum Lp(a) concentration and unsuccessful thrombolysis after acute myocardial infarction.
    Armstrong VW; Neubauer C; Schütz E; Tebbe U
    Lancet; 1990 Oct; 336(8722):1077. PubMed ID: 1977059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.